| For: | Keeffe EB, Rossignol JF. Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides. World J Gastroenterol 2009; 15(15): 1805-1808 [PMID: 19370775 DOI: 10.3748/wjg.15.1805] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v15/i15/1805.htm |
| Number | Citing Articles |
| 1 |
Raúl Romero-Cabello, Raúl Romero-Feregrino, Rodrigo Romero-Feregrino, Octavio Amancio Chassin. Uso de nitazoxanida en infecciones virales. Revista Latinoamericana de Infectología Pediátrica 2021; 34(2) doi: 10.35366/100548
|
| 2 |
Ester Lopez-Suñé, Montse Tuset, Montse Laguno, Asunción Moreno, José M. Miró. Características de los fármacos antivíricos activos frente al virus de la hepatitis y el virus de la influenza: actualización 2009. Enfermedades Infecciosas y Microbiología Clínica 2010; 28(4) doi: 10.1016/j.eimc.2010.02.001
|
| 3 |
Daniel Grimm, Robert Thimme, Hubert E. Blum. HBV life cycle and novel drug targets. Hepatology International 2011; 5(2) doi: 10.1007/s12072-011-9261-3
|
| 4 |
Mahmoud Saleh, Yaser A. Mostafa, Jyothi Kumari, Momen M. Thabet, Dharmarajan Sriram, Mahmoud Kandeel, Hajjaj H. M. Abdu-Allah. New nitazoxanide derivatives: design, synthesis, biological evaluation, and molecular docking studies as antibacterial and antimycobacterial agents. RSC Medicinal Chemistry 2023; 14(12) doi: 10.1039/D3MD00449J
|
| 5 |
Flavia P. Bruno, Mino R. Caira, Gustavo A. Monti, Diego E. Kassuha, Norma R. Sperandeo. Spectroscopic, thermal and X-ray structural study of the antiparasitic and antiviral drug nitazoxanide. Journal of Molecular Structure 2010; 984(1-3) doi: 10.1016/j.molstruc.2010.09.006
|
| 6 |
Siyu Xu, Naomichi Yamamoto. Anti-infective nitazoxanide disrupts transcription of ribosome biogenesis-related genes in yeast. Genes & Genomics 2020; 42(8) doi: 10.1007/s13258-020-00958-0
|
| 7 |
Ana Clara M. Oliveira, Eduardo M. Richter, Thiago R.L.C. Paixão, Diele A.G. Araújo, Rodrigo A.A. Muñoz. Electrochemical determination of nitazoxanide in environmental and pharmaceutical samples using a boron-doped diamond electrode. Microchemical Journal 2024; 207 doi: 10.1016/j.microc.2024.112162
|
| 8 |
Catherine-Audrey Boutin, M. Callegari, D. Florescu, M.H. Nguyen, D. Kaul, R. Avery, P. Chong, C. Fisher, A.P. Limaye, L. Clough, S.A. Pergam, M. Green, M.G. Michaels, L. Danziger-Isakov, M. Angarone, L. Keefer, A. Daud, R. Lorenzo-Redondo, M. Tan, M.G. Ison. A Phase 2 Multi-Center, Prospective, Randomized, Double-Blind Study to Assess the Clinical and Antiviral Efficacy and Safety of Nitazoxanide for the Treatment of Norovirus in Hematopoietic Stem Cell and Solid Organ Transplant Recipients. American Journal of Transplantation 2026; doi: 10.1016/j.ajt.2026.04.010
|
| 9 |
Danish M. Siddiq, Hoonmo L. Koo, Javier A. Adachi, George M. Viola. Norovirus gastroenteritis successfully treated with nitazoxanide. Journal of Infection 2011; 63(5) doi: 10.1016/j.jinf.2011.08.002
|
| 10 |
Na Liu, Fabao Zhao, Haiyong Jia, Diwakar Rai, Peng Zhan, Xuemei Jiang, Xinyong Liu. Non-nucleoside anti-HBV agents: advances in structural optimization and mechanism of action investigations. MedChemComm 2015; 6(4) doi: 10.1039/C4MD00521J
|
| 11 |
Luiz Pedro S. de Carvalho, Gang Lin, Xiuju Jiang, Carl Nathan. Nitazoxanide Kills Replicating and Nonreplicating Mycobacterium tuberculosis and Evades Resistance. Journal of Medicinal Chemistry 2009; 52(19) doi: 10.1021/jm9010719
|
| 12 |
Stevan A Gonzalez, Emmet B Keeffe. Chronic Hepatitis B and C: Update on Therapy. Future Virology 2009; 4(5) doi: 10.2217/fvl.09.43
|
| 13 |
Abd-Elgawad Radi, Hossam M. Nassef, Abd-Elrahman El-Naggar. Electrochemical and spectral characterization of the host-guest inclusion complex of the antiparasitic drug nitazoxanide with β-cyclodextrin. Monatshefte für Chemie - Chemical Monthly 2014; 145(3) doi: 10.1007/s00706-013-1109-1
|
| 14 |
Frederic Vigant, Nuno C. Santos, Benhur Lee. Broad-spectrum antivirals against viral fusion. Nature Reviews Microbiology 2015; 13(7) doi: 10.1038/nrmicro3475
|
| 15 |
Joao M. Serigado, Manhal Izzy, Harmit Kalia. Novel therapies and potential therapeutic targets in the management of chronic hepatitis B. European Journal of Gastroenterology & Hepatology 2017; 29(9) doi: 10.1097/MEG.0000000000000911
|
| 16 |
Latavia Singh, Sunaina Indermun, Mershen Govender, Pradeep Kumar, Lisa C. Du Toit, Yahya E. Choonara, Viness Pillay. Drug Delivery Strategies for Antivirals against Hepatitis B Virus. Viruses 2018; 10(5) doi: 10.3390/v10050267
|
| 17 |
R. F. Schinazi, L. Bassit, C. Gavegnano. HCV drug discovery aimed at viral eradication. Journal of Viral Hepatitis 2010; 17(2) doi: 10.1111/j.1365-2893.2009.01246.x
|
| 18 |
Khaled Mosaad Elhusseiny, Fatma Abd-Elshahed Abd-Elhay, Mohamed Gomaa Kamel. Possible therapeutic agents for COVID-19: a comprehensive review. Expert Review of Anti-infective Therapy 2020; 18(10) doi: 10.1080/14787210.2020.1782742
|
| 19 |
Masahito Minami. Future therapy for hepatitis B virus infection. Clinical Journal of Gastroenterology 2015; 8(4) doi: 10.1007/s12328-015-0590-y
|
| 20 |
Abd-Elgawad Radi, Nadia Abd El-Ghany, Tarek Wahdan. Anodic voltammetric methods for determination of the antiparasitic drug nitazoxanide in bulk form, pharmaceutical formulation, and its metabolite tizoxanide in human serum. Monatshefte für Chemie - Chemical Monthly 2012; 143(5) doi: 10.1007/s00706-011-0636-x
|
| 21 |
Mohammad Rashidul Hashan, Khaled Mosaad Elhusseiny, Le Huu-Hoai, Thuan Minh Tieu, Soon Khai Low, Le Huu Nhat Minh, Thai Le Ba Nghia, Le Quang Loc, Mai Nhu Y, Peter Samuel Eid, Mohammed Abed, Salma Said Elkolaly, Gehad Mohamed Tawfik, Nguyen Tien Huy. Effect of nitazoxanide on diarrhea: A systematic review and network meta-analysis of randomized controlled trials. Acta Tropica 2020; 210 doi: 10.1016/j.actatropica.2020.105603
|
| 22 |
Rizwan Bashir, Sobia Jabeen, Wasim Abbas, Fazal-e Habib, Shoaib Iqbal, Moazur Rahman, Waqar Rauf, Mazhar Iqbal. Enhancing thiazolide efficacy: C-4 aryl modifications drive selective SARS-CoV-2 inhibition. Future Medicinal Chemistry 2025; 17(18) doi: 10.1080/17568919.2025.2559572
|
| 23 |
Wosen Aman, Shaymaa Mousa, Gamal Shiha, Shaker A Mousa. Current status and future directions in the management of chronic hepatitis C. Virology Journal 2012; 9(1) doi: 10.1186/1743-422X-9-57
|
| 24 |
Brenda C. Félix-Sonda, Jesús Rivera-Islas, Dea Herrera-Ruiz, Hugo Morales-Rojas, Herbert Höpfl. Nitazoxanide Cocrystals in Combination with Succinic, Glutaric, and 2,5-Dihydroxybenzoic Acid. Crystal Growth & Design 2014; 14(3) doi: 10.1021/cg4015916
|
| 25 |
Meng-Che Lu, Sheng-Chieh Lin, Yi-Hsiang Hsu, Shih-Yen Chen. Epidemiology, Clinical Features, and Unusual Complications of Norovirus Infection in Taiwan: What We Know after Rotavirus Vaccines. Pathogens 2022; 11(4) doi: 10.3390/pathogens11040451
|
| 26 |
Divya Samantha Kondapi, Sasirekha Ramani, Mary K Estes, Robert L Atmar, Pablo C Okhuysen. Norovirus in Cancer Patients: A Review. Open Forum Infectious Diseases 2021; 8(6) doi: 10.1093/ofid/ofab126
|
| 27 |
Ludmila Perelygina, Timo Hautala, Mikko Seppänen, Adebola Adebayo, Kathleen E. Sullivan, Joseph Icenogle. Inhibition of rubella virus replication by the broad-spectrum drug nitazoxanide in cell culture and in a patient with a primary immune deficiency. Antiviral Research 2017; 147 doi: 10.1016/j.antiviral.2017.09.019
|
| 28 |
Noha Ghusson, Gustavo Vasquez. Successfully Treated Norovirus- and Sapovirus-Associated Diarrhea in Three Renal Transplant Patients. Case Reports in Infectious Diseases 2018; 2018 doi: 10.1155/2018/6846873
|
| 29 |
Simone I. Strasser. Drugs in Development for the Treatment of Chronic Hepatitis B. Current Hepatitis Reports 2012; 11(2) doi: 10.1007/s11901-012-0131-9
|
| 30 |
Yameng Pei, Chunting Wang, S. Frank Yan, Gang Liu. Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection. Journal of Medicinal Chemistry 2017; 60(15) doi: 10.1021/acs.jmedchem.6b01442
|
| 31 |
Hongzhuan Zhou, Xia Su, Lulu Lin, Jin Zhang, Qi Qi, Fangfang Guo, Fuzhou Xu, Bing Yang. Inhibitory Effects of Antiviral Drug Candidates on Canine Parvovirus in F81 cells. Viruses 2019; 11(8) doi: 10.3390/v11080742
|
| 32 |
Andrew V. Stachulski, Joshua Taujanskas, Sophie L. Pate, Rajith K. R. Rajoli, Ghaith Aljayyoussi, Shaun H. Pennington, Stephen A. Ward, Weiqian David Hong, Giancarlo A. Biagini, Andrew Owen, Gemma L. Nixon, Suet C. Leung, Paul M. O’Neill. Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?. ACS Infectious Diseases 2021; 7(6) doi: 10.1021/acsinfecdis.0c00478
|
| 33 |
María L. Cuestas, Verónica L. Mathet, José R. Oubiña, Alejandro Sosnik. Drug Delivery Systems and Liver Targeting for the Improved Pharmacotherapy of the Hepatitis B Virus (HBV) Infection. Pharmaceutical Research 2010; 27(7) doi: 10.1007/s11095-010-0112-z
|
| 34 |
Laura V. Ashton, Robert L. Callan, Sangeeta Rao, Gabriele A. Landolt. In VitroSusceptibility of Canine Influenza A (H3N8) Virus to Nitazoxanide and Tizoxanide. Veterinary Medicine International 2010; 2010 doi: 10.4061/2010/891010
|
| 35 |
Michael A. Gelman, Jeffrey S. Glenn. Mixing the right hepatitis C inhibitor cocktail. Trends in Molecular Medicine 2011; 17(1) doi: 10.1016/j.molmed.2010.10.005
|
| 36 |
Jianzhong Cao, J. Craig Forrest, Xuming Zhang. A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs. Antiviral Research 2015; 114 doi: 10.1016/j.antiviral.2014.11.010
|
| 37 |
Pasquale Pagliano, Giuliana Scarpati, Carmine Sellitto, Valeria Conti, Anna Maria Spera, Tiziana Ascione, Ornella Piazza, Amelia Filippelli. Experimental Pharmacotherapy for COVID-19: The Latest Advances. Journal of Experimental Pharmacology 2021; doi: 10.2147/JEP.S255209
|
| 38 |
Z. M. Zhu, W. J. Zhang. Spectroscopic Analysis of the Interaction Between the Antiparasitic Drug Nitazoxanide and Bovine Serum Albumin. Iranian Journal of Science and Technology, Transactions A: Science 2021; 45(3) doi: 10.1007/s40995-021-01102-7
|